Evaluates antihyperglycemic effects in rats, highlighting plant extract's potential benefits.
This study evaluates the antihyperglycemic effect of the aqueous leaf extract of Lecaniodiscus cupanioides (EAq Lc) in Wistar rats made diabetic by alloxan. The animals were divided into five groups and treated orally with the extract at doses of 250 and 500 mg/kg, compared to a control group receiving glibenclamide (100 mg/kg). The results show a significant reduction in blood glucose, serum urea, and serum creatinine, as well as normalization of liver markers (ASAT, ALAT, PAL). At a dose of 500 mg/kg body weight, the extract reduced blood glucose levels by 81.68% compared to those of the diabetic control rats, urea by 58.9%, creatinine by 57.96%, aspartate aminotransferase (ASAT) by 42.34%, and alkaline phosphatase (ALP). The extract at 250 mg/kg bw also reduced alanine aminotransferase (ALT) by 68.57% compared to the diabetic control. Thus, the aqueous extract of Lecaniodiscus cupanioides (EAq Lc) regenerated pancreatic β-cells and restored hepatic and renal markers.
No takes yet. Share an insight, caveat, or question.
TRAORÉ Zeinab1*, YEO Sounta Oumar1,3, KOUAMÉ Djè Kouamé Wenceslas2, SILUÉ Kalamourou1, et DOUMBIA Idrissa1,3 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: